QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NYSE:OGN

Organon & Co. (OGN) Competitors

$16.29
-0.40 (-2.40%)
(As of 10/3/2023 ET)
Compare
Today's Range
$16.13
$16.67
50-Day Range
$16.29
$23.77
52-Week Range
$16.13
$32.43
Volume
2.75 million shs
Average Volume
2.20 million shs
Market Capitalization
$4.16 billion
P/E Ratio
5.52
Dividend Yield
6.88%
Price Target
$28.25

OGN vs. BBIO, PRGO, ALKS, ACAD, APLS, INSM, ITCI, IMGN, FOLD, and EVO

Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include BridgeBio Pharma (BBIO), Perrigo (PRGO), Alkermes (ALKS), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Insmed (INSM), Intra-Cellular Therapies (ITCI), ImmunoGen (IMGN), Amicus Therapeutics (FOLD), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.

Organon & Co. vs.

Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.

Organon & Co. has a net margin of 12.22% compared to BridgeBio Pharma's net margin of -10,096.65%. BridgeBio Pharma's return on equity of 0.00% beat Organon & Co.'s return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.12.22% -142.40% 10.73%
BridgeBio Pharma -10,096.65%N/A -91.14%

Organon & Co. has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Organon & Co. currently has a consensus price target of $28.25, indicating a potential upside of 73.42%. BridgeBio Pharma has a consensus price target of $37.30, indicating a potential upside of 46.68%. Given Organon & Co.'s higher probable upside, equities research analysts clearly believe Organon & Co. is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
BridgeBio Pharma
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

BridgeBio Pharma received 114 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 65.80% of users gave BridgeBio Pharma an outperform vote while only 32.50% of users gave Organon & Co. an outperform vote.

CompanyUnderperformOutperform
Organon & Co.Outperform Votes
13
32.50%
Underperform Votes
27
67.50%
BridgeBio PharmaOutperform Votes
127
65.80%
Underperform Votes
66
34.20%

77.1% of Organon & Co. shares are held by institutional investors. Comparatively, 90.9% of BridgeBio Pharma shares are held by institutional investors. 1.2% of Organon & Co. shares are held by insiders. Comparatively, 28.5% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.17B0.67$917M$2.955.52
BridgeBio Pharma$77.65M53.21-$481.18M-$3.75-6.78

In the previous week, BridgeBio Pharma had 1 more articles in the media than Organon & Co.. MarketBeat recorded 6 mentions for BridgeBio Pharma and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.78 beat BridgeBio Pharma's score of 0.69 indicating that Organon & Co. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BridgeBio Pharma
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BridgeBio Pharma beats Organon & Co. on 10 of the 18 factors compared between the two stocks.


Get Organon & Co. News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

MetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$4.16B$6.05B$4.44B$14.74B
Dividend Yield6.45%2.73%5.94%3.77%
P/E Ratio5.527.13126.5421.74
Price / Sales0.67180.302,896.2012.92
Price / Cash2.9519.0421.4715.12
Price / Book-4.644.003.816.48
Net Income$917M$202.28M$121.45M$900.60M
7 Day Performance-5.57%-2.09%-2.26%-2.27%
1 Month Performance-26.42%-11.76%-8.21%-8.55%
1 Year Performance-32.32%2.75%6.56%4.17%

Organon & Co. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBIO
BridgeBio Pharma
2.5725 of 5 stars
$26.58
-1.8%
$37.30
+40.3%
+155.6%$4.32B$77.65M-7.09392
PRGO
Perrigo
3.1229 of 5 stars
$31.47
-2.2%
$46.67
+48.3%
-12.1%$4.26B$4.45B-74.938,900Positive News
ALKS
Alkermes
2.2604 of 5 stars
$28.97
-0.4%
$33.33
+15.1%
+25.7%$4.83B$1.46B50.832,280
ACAD
ACADIA Pharmaceuticals
2.3687 of 5 stars
$23.63
+1.5%
$31.81
+34.6%
+31.2%$3.87B$517.23M-34.25540Short Interest ↑
APLS
Apellis Pharmaceuticals
2.5845 of 5 stars
$43.18
+0.2%
$66.13
+53.2%
-45.6%$5.08B$75.42M-7.41767Short Interest ↑
INSM
Insmed
2.1715 of 5 stars
$25.77
0.0%
$43.71
+69.6%
+17.8%$3.71B$269.47M-4.91373Short Interest ↑
ITCI
Intra-Cellular Therapies
2.7233 of 5 stars
$53.75
-1.0%
$78.78
+46.6%
+12.8%$5.16B$250.31M-27.85561Short Interest ↓
Positive News
IMGN
ImmunoGen
2.5852 of 5 stars
$14.97
+2.3%
$22.88
+52.8%
+229.9%$3.64B$189.56M-20.79277
FOLD
Amicus Therapeutics
2.1564 of 5 stars
$12.24
+2.3%
$15.20
+24.2%
+5.7%$3.51B$329.23M-19.13484Analyst Revision
EVO
Evotec
1.9744 of 5 stars
$9.83
-2.9%
$14.00
+42.4%
N/A$3.48B$791.73M0.004,952High Trading Volume

Related Companies and Tools

This page (NYSE:OGN) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -